Developer docs
API playgroundTry for free, no card

Search company profiles

SightGlass Vision

Full company profile

uuid0006ocs

Namestring
SightGlass Vision
Legal namestring
SightGlass Vision, Inc.
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Short text here

Short descriptiontext

SightGlass Vision is a medical device company that develops DOT (Diffusion Optics Technology) spectacle lenses to slow myopia progression in children aged 6–13, selling wholesale to eye care professionals and optical retailers across Europe, Asia-Pacific, and Canada.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersDallas, United States
HQ citystring
Dallas
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
myopia control lenses, pediatric ophthalmology devices, diffusion optics technology, contrast management therapy, spectacle lens innovation
Industry2 codes
PRIMARYHLAHAJAD
Optical Dispensing & Eyewear Devices (Frames, Lenses, Lens Edging/Finishing Equipment)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAHAJAM
Pediatric Ophthalmology & Orthoptics Devices (Amblyopia Therapy, Strabismus Measurement & Treatment)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
NAICS code1 code
  • Ophthalmic Goods Manufacturing339115
SIC code1 code
  • Ophthalmic Goods3851
Product category
Myopia Control Spectacle Lenses
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1DOT Spectacle Lens Sales (B2B)
TypeOne Time License
Description

SightGlass Vision sells its DOT spectacle lenses to eye care professionals (optometrists, opticians, ophthalmologists) and optical retailers on a wholesale B2B basis. Eye care professionals then dispense the lenses to patients (children with myopia). Revenue is generated through product sales to the trade, with pricing governed by contracts and price lists. Products are distributed via approved sales channels in markets where commercially available.

sightglassvision.com
2Professional Services and Training
TypeProfessional Services
Description

The company provides professional education, clinical resources, and training materials to eye care professionals to support adoption and correct fitting of DOT lenses. This supports the core product revenue stream by driving prescription volumes.

sightglassvision.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Marketing or Sales, Supply Chain, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1DOT (Diffusion Optics Technology)
Description

DOT spectacle lenses use thousands of light scattering elements called dots that mimic more natural contrast on the retina to slow myopia progression in children.

sightglassvision.com
Core offering1 text field

SightGlass Vision develops and commercializes DOT (Diffusion Optics Technology) spectacle lenses designed to slow myopia progression in children aged 6-13. The lenses integrate thousands of light-scattering micro-dots that reduce artificial contrast signals reaching the retina, addressing the root cause of childhood myopia. Products are manufactured and distributed through channel partners and the joint venture's global optical infrastructure, with clinical backing from multi-year trials showing up to 75% reduction in myopia progression after 12 months of wear.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • 75% reduction in cycloplegic spherical equivalent refraction (cSER) progression after 12 months of wear in Chinese children (CATHAY trial)
+7 more records
Product overview1 text field

SightGlass Vision offers a single unified product: DOT™ (Diffusion Optics Technology™) spectacle lenses for myopia control in children. The flagship product integrates thousands of light-scattering elements called dots that mimic natural contrast at all distances. The lenses correct vision while simultaneously slowing myopia progression through contrast management. The product has completed the pivotal three-year CYPRESS multi-site clinical study and is available in markets including China, Canada, Netherlands, Israel, Spain, and the U.K. The company operates as a joint venture of CooperCompanies and EssilorLuxottica. SightGlass Vision does not sell products in the United States.

Product and service2 records
1DOT (Diffusion Optics Technology) Spectacle Lenses
CategoryMyopia Control Spectacle Lenses
Description

Prescription spectacle lenses integrating thousands of light-scattering micro-dots that reduce retinal contrast to slow myopia progression in children aged 6-13. Dispensed exclusively through qualified eye care professionals (optometrists, dispensing opticians, ophthalmologists).

2DOT 0.2 Spectacle Lenses
CategoryMyopia Control Spectacle Lenses
Description

Specific DOT lens variant with a 0.2 diffusion level used in the CYPRESS (North American) and CATHAY (Chinese) clinical trials, demonstrating up to 75% reduction in myopia progression after 12 months in children aged 6-13.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-04-14
Description

Nikon Lenswear is the exclusive commercial partner for DOT lens distribution in China, announced at COOC 2023. SightGlass Vision and Nikon Lenswear co-present at COOC, with Nikon handling local commercialization of DOT lenses in China. Nikon Lenswear and SightGlass Vision collaborate on product demonstrations, case reviews, and clinical trial result presentations with Chinese eye care key opinion leaders.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

HOYA's MiyoSmart uses DIMS (Defocus Incorporated Multiple Segments) technology to slow myopia progression in children via spectacle lenses — the closest direct competitor to SightGlass Vision's DOT, targeting the same pediatric population and ECP channel with a different optical mechanism.

TypeDirect peer
Description

Essilor's Stellest spectacle lenses, built on highly aspherical lenslet technology, compete head-to-head with DOT in pediatric myopia control. EssilorLuxottica is also a parent JV partner of SightGlass Vision, creating both collaboration and channel-conflict dynamics.

TypeDirect peer
Description

CooperVision's MiSight 1 day is the first FDA-approved contact lens for myopia control in children and is the leading non-spectacle alternative. CooperVision distributes DOT in Canada and is also a parent JV partner of SightGlass Vision, situating it as both peer and partner.

TypeEmerging player
Description

Menicon has developed myopia control contact lenses and orthokeratology solutions targeting the same pediatric population. As an emerging player with growing clinical data, it overlaps with DOT in indication and prescriber base.

TypeBroad incumbent
Description

J&J Vision is a broad incumbent in contact lenses and pediatric vision care. Its recent moves into myopia management overlap with DOT's target market of children with progressive myopia.

TypeBroad incumbent
Description

Bausch + Lomb offers vision care products including contact lenses and ophthalmic devices, with interests in myopia management, serving overlapping ECP and pediatric patient populations as DOT.

7Carl Zeiss Meditec
TypeBroad incumbent
Description

Zeiss produces ophthalmic devices, lens coatings, and vision diagnostics. As a broad incumbent in optical instrumentation and lens technology, it is comparable to SightGlass Vision in the ophthalmic device and eyewear technology space.

TypeRegional player
Description

Nikon Lenswear is the exclusive distribution partner for DOT lenses in China and produces its own corrective spectacle lenses. It serves the same pediatric myopia market in a specific geography and is both a commercial partner and adjacent competitor to SightGlass Vision.

TypeEmerging player
Description

Ocumetra provides myopia management software, risk calculators, and outcome simulation tools for eye care professionals — including hosting the DOT Vision Simulator on SightGlass Vision's website. It targets the same ECP/pediatric-myopia workflow as DOT.

TypeEmerging player
Description

Eyerising develops repeated low-level red-light therapy devices for childhood myopia control, representing an emerging non-lens intervention that intersects with DOT's pediatric myopia indication at the ECP-prescription layer.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SightGlass Vision

Myopia Control Spectacle Lensessightglassvision.com

SightGlass Vision is a medical device company that develops DOT (Diffusion Optics Technology) spectacle lenses to slow myopia progression in children aged 6–13, selling wholesale to eye care professionals and optical retailers across Europe, Asia-Pacific, and Canada.

What SightGlass Vision does

Short text here

SightGlass Vision firmographics

Firmographics
Name
SightGlass Vision
Legal name
SightGlass Vision, Inc.
Website
https://sightglassvision.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
SightGlass Vision is a medical device company that develops DOT (Diffusion Optics Technology) spectacle lenses to slow myopia progression in children aged 6–13, selling wholesale to eye care professionals and optical retailers across Europe, Asia-Pacific, and Canada.
Ownership category
akta.pro rank

SightGlass Vision industry classification

Industry
Product category
Myopia Control Spectacle Lenses
NAICS
Ophthalmic Goods Manufacturing (339115)
SIC
Ophthalmic Goods (3851)
akta.pro industry
PRIMARYHLAHAJAD
Optical Dispensing & Eyewear Devices (Frames, Lenses, Lens Edging/Finishing Equipment)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAHAJAM
Pediatric Ophthalmology & Orthoptics Devices (Amblyopia Therapy, Strabismus Measurement & Treatment)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)

Keywords

  • Myopia control lenses
  • Pediatric ophthalmology devices
  • Diffusion optics technology
  • Contrast management therapy
  • Spectacle lens innovation

Where SightGlass Vision is headquartered

Location

Headquarters

HQ city
Dallas
HQ country
United States
HQ region
North America

Offices5 records

Markets served

SightGlass Vision business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Marketing or Sales, Supply Chain, Personnel, Operations

Revenue model

  1. DOT Spectacle Lens Sales (B2B): SightGlass Vision sells its DOT spectacle lenses to eye care professionals (optometrists, opticians, ophthalmologists) and optical retailers on a wholesale B2B basis. Eye care professionals then dispense the lenses to patients (children with myopia). Revenue is generated through product sales to the trade, with pricing governed by contracts and price lists. Products are distributed via approved sales channels in markets where commercially available.
  2. Professional Services and Training: The company provides professional education, clinical resources, and training materials to eye care professionals to support adoption and correct fitting of DOT lenses. This supports the core product revenue stream by driving prescription volumes.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels8 records

SightGlass Vision product offering

Product offering

Core offering

SightGlass Vision develops and commercializes DOT (Diffusion Optics Technology) spectacle lenses designed to slow myopia progression in children aged 6-13. The lenses integrate thousands of light-scattering micro-dots that reduce artificial contrast signals reaching the retina, addressing the root cause of childhood myopia. Products are manufactured and distributed through channel partners and the joint venture's global optical infrastructure, with clinical backing from multi-year trials showing up to 75% reduction in myopia progression after 12 months of wear.

Product overview

SightGlass Vision offers a single unified product: DOT™ (Diffusion Optics Technology™) spectacle lenses for myopia control in children. The flagship product integrates thousands of light-scattering elements called dots that mimic natural contrast at all distances. The lenses correct vision while simultaneously slowing myopia progression through contrast management. The product has completed the pivotal three-year CYPRESS multi-site clinical study and is available in markets including China, Canada, Netherlands, Israel, Spain, and the U.K. The company operates as a joint venture of CooperCompanies and EssilorLuxottica. SightGlass Vision does not sell products in the United States.

Differentiator

Problem solved

Functional benefit

Brands

  • DOT (Diffusion Optics Technology): DOT spectacle lenses use thousands of light scattering elements called dots that mimic more natural contrast on the retina to slow myopia progression in children.

Products and services

  • DOT (Diffusion Optics Technology) Spectacle Lenses Prescription spectacle lenses integrating thousands of light-scattering micro-dots that reduce retinal contrast to slow myopia progression in children aged 6-13. Dispensed exclusively through qualified eye care professionals (optometrists, dispensing opticians, ophthalmologists).
  • DOT 0.2 Spectacle Lenses Specific DOT lens variant with a 0.2 diffusion level used in the CYPRESS (North American) and CATHAY (Chinese) clinical trials, demonstrating up to 75% reduction in myopia progression after 12 months in children aged 6-13.

Quantifiable outcome

  • 75% reduction in cycloplegic spherical equivalent refraction (cSER) progression after 12 months of wear in Chinese children (CATHAY trial)
  • +7 more outcomes

Companies that use SightGlass Vision

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

SightGlass Vision technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

SightGlass Vision partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Nikon LenswearcoreChannel Partner/ Reseller/ Distributor · 14 April 2023Nikon Lenswear is the exclusive commercial partner for DOT lens distribution in China, announced at COOC 2023. SightGlass Vision and Nikon Lenswear co-present at COOC, with Nikon handling local commercialization of DOT lenses in China. Nikon Lenswear and SightGlass Vision collaborate on product demonstrations, case reviews, and clinical trial result presentations with Chinese eye care key opinion leaders.

Scale indicators8 records

Recent moves5 records

Expansion highlights6 records

SightGlass Vision competitors and assessment

Company assessment

Direct peers

  • HOYA Corporation (MiyoSmart): HOYA's MiyoSmart uses DIMS (Defocus Incorporated Multiple Segments) technology to slow myopia progression in children via spectacle lenses — the closest direct competitor to SightGlass Vision's DOT, targeting the same pediatric population and ECP channel with a different optical mechanism.
  • EssilorLuxottica (Stellest lenses): Essilor's Stellest spectacle lenses, built on highly aspherical lenslet technology, compete head-to-head with DOT in pediatric myopia control. EssilorLuxottica is also a parent JV partner of SightGlass Vision, creating both collaboration and channel-conflict dynamics.
  • CooperVision (MiSight): CooperVision's MiSight 1 day is the first FDA-approved contact lens for myopia control in children and is the leading non-spectacle alternative. CooperVision distributes DOT in Canada and is also a parent JV partner of SightGlass Vision, situating it as both peer and partner.

Emerging players

  • Menicon (Miru): Menicon has developed myopia control contact lenses and orthokeratology solutions targeting the same pediatric population. As an emerging player with growing clinical data, it overlaps with DOT in indication and prescriber base.
  • Ocumetra: Ocumetra provides myopia management software, risk calculators, and outcome simulation tools for eye care professionals — including hosting the DOT Vision Simulator on SightGlass Vision's website. It targets the same ECP/pediatric-myopia workflow as DOT.
  • Eyerising International: Eyerising develops repeated low-level red-light therapy devices for childhood myopia control, representing an emerging non-lens intervention that intersects with DOT's pediatric myopia indication at the ECP-prescription layer.

Broad incumbents

  • Johnson & Johnson Vision: J&J Vision is a broad incumbent in contact lenses and pediatric vision care. Its recent moves into myopia management overlap with DOT's target market of children with progressive myopia.
  • Bausch + Lomb: Bausch + Lomb offers vision care products including contact lenses and ophthalmic devices, with interests in myopia management, serving overlapping ECP and pediatric patient populations as DOT.
  • Carl Zeiss Meditec: Zeiss produces ophthalmic devices, lens coatings, and vision diagnostics. As a broad incumbent in optical instrumentation and lens technology, it is comparable to SightGlass Vision in the ophthalmic device and eyewear technology space.

Regional players

  • Nikon Lenswear: Nikon Lenswear is the exclusive distribution partner for DOT lenses in China and produces its own corrective spectacle lenses. It serves the same pediatric myopia market in a specific geography and is both a commercial partner and adjacent competitor to SightGlass Vision.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

SightGlass Vision social profiles

Digital presence

SightGlass Vision financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SightGlass Vision leadership team

Management profile

Number of profiles

Profiles7 records

SightGlass Vision subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

SightGlass Vision funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SightGlass Vision M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SightGlass Vision

What does SightGlass Vision do?

SightGlass Vision develops and commercializes DOT (Diffusion Optics Technology) spectacle lenses designed to slow myopia progression in children aged 6-13. The lenses integrate thousands of light-scattering micro-dots that reduce artificial contrast signals reaching the retina, addressing the root cause of childhood myopia. Products are manufactured and distributed through channel partners and the joint venture's global optical infrastructure, with clinical backing from multi-year trials showing up to 75% reduction in myopia progression after 12 months of wear.

Is SightGlass Vision a public or private company?

SightGlass Vision is a private company. It is classified as corporate owned and is currently operating.

When was SightGlass Vision founded?

SightGlass Vision was founded in 2016. It employs 11 to 50 people.

Where is SightGlass Vision based?

SightGlass Vision is headquartered in Dallas, United States, in the North America region.

How does SightGlass Vision make money?

Two revenue lines are on record. DOT Spectacle Lens Sales (B2B) is the primary driver. The others are professional Services and Training.

Who are SightGlass Vision's main competitors?

Direct peers on record are HOYA Corporation (MiyoSmart), EssilorLuxottica (Stellest lenses) and CooperVision (MiSight). Emerging players are Menicon (Miru), Ocumetra and Eyerising International. Broad incumbents are Johnson & Johnson Vision, Bausch + Lomb and Carl Zeiss Meditec. Nikon Lenswear is listed as a regional player.

Does SightGlass Vision have an API?

No public API is recorded for SightGlass Vision.

What industry is SightGlass Vision in?

SightGlass Vision's product category is Myopia Control Spectacle Lenses. Its primary akta.pro industry code is HLAHAJAD, Optical Dispensing & Eyewear Devices (Frames, Lenses, Lens Edging/Finishing Equipment), with a secondary code of HLAHAJAM, Pediatric Ophthalmology & Orthoptics Devices (Amblyopia Therapy, Strabismus Measurement & Treatment). Its NAICS code is 339115 and its SIC code is 3851.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
VisionmondaySightGlass Vision Named Healthtech Company of the Year Finalist by UK Business Tech AwardsSightGlass Vision, a joint venture of CooperCompanies and EssilorLuxottica, has been named a finalist for Healthtech Company of the Year at the UK Business Tech Awards. The company reported that its DOT spectacle lenses have surpassed two million wearers, with new two-year clinical trial data from China showing the lenses reduced myopia progression by more than 1 diopter on average in children ages 6 to 10. The nomination comes as SightGlass Vision, founded in 2016, seeks to establish its treatment as a go-to approach for myopia control in the UK market.CoopervisionsecPress release introduction SightGlass Vision™CooperVision has launched SightGlass Vision™ spectacle lenses in the Netherlands, marking the first commercial availability of this technology in Europe. The lenses utilize Diffusion Optics Technology to slow myopia progression in children aged six and older, with clinical studies showing a 47% reduction in progression rates over two years.PR NewswireSightGlass Vision Receives Breakthrough Device Designation from U.S. Food and Drug AdministrationSightGlass Vision announced that the U.S. Food and Drug Administration granted Breakthrough Device designation to its Diffusion Optics Technology (DOT) spectacle lenses, intended to slow myopia progression in children. The designation provides the company with more frequent FDA feedback and prioritized submission review during the premarket phase. The lenses have already launched commercially in China, the Netherlands, and Israel, with full four-year clinical trial data from the CYPRESS study showing statistically significant slowing of axial length progression.Business & FinancialSightglass Vision Receives Breakthrough Device Designation From U.S. Food And Drug AdministrationThe FDA granted Breakthrough Device designation to SightGlass Vision's Diffusion Optics Technology spectacle lenses for slowing myopia progression in children. The lenses use a contrast management mechanism with thousands of light-scattering elements. The company plans to pursue U.S. market clearance.GlobeNewswireEssilorLuxottica: SightGlass Vision Joint Venture Begins OperationEssilorLuxottica and CooperCompanies finalized their joint venture agreement for SightGlass Vision, which begins operations. The venture commercializes Diffusion Optics Technology, a spectacle lens with micro-dots to reduce myopia progression in children. Myopia affects 2.6 billion people globally, with nearly 5 billion expected by 2050.GlobeNewswireSightGlass Vision Joint Venture Begins OperationEssilorLuxottica and CooperCompanies finalized their joint venture agreement for SightGlass Vision, accelerating commercialization of myopia management spectacle lenses. The technology uses micro-dots to scatter light and reduce myopia progression in children. The company notes myopia affects 2.6 billion people globally, with nearly 5 billion expected by 2050.GlobeNewswireEssilorLuxottica : EssilorLuxottica and CooperCompanies Announce Joint Venture for Acquisition of SightGlass VisionEssilorLuxottica and CooperCompanies announced a 50/50 joint venture to acquire SightGlass Vision, a U.S. life sciences company developing spectacle lenses to reduce myopia progression in children. Myopia affects 2.6 billion people worldwide, with nearly 5 billion expected by 2050. The acquisition is subject to regulatory approvals and customary closing conditions.CoopercosEssilorLuxottica and CooperCompanies Announce Joint Venture for Acquisition of SightGlass VisionEssilorLuxottica and CooperCompanies have entered into an agreement to form a 50/50 joint venture for the acquisition of SightGlass Vision, a U.S. life sciences company developing spectacle lenses to reduce myopia progression in children. The partnership aims to leverage complementary technologies including Essilor's Stellest lens and CooperVision's MiSight and Orthokeratology contact lenses to accelerate commercialization and address a condition currently affecting 2.6 billion people worldwide. The acquisition is subject to regulatory approvals and other customary closing conditions, with CooperCompanies having previously completed its full acquisition of SightGlass Vision in January 2021.PR NewswireSightGlass Vision Achieves CE Mark Allowing European Marketing Authorization for Novel Eyeglasses That Slow Myopia Progression in ChildrenSightGlass Vision, Inc. announced it has achieved CE Mark declaration for its novel Diffusion Optics Technology (DOT) spectacle lenses designed to slow myopia progression in children, allowing commercialization across the European Union, United Kingdom, and other European Economic Area countries. The DOT lenses are the first product to show success in a multi-center, randomized, controlled clinical trial while including anti-reflective and photochromic options for myopia management. The company, headquartered in Palo Alto, California, was founded in 2016 based on research from the University of Washington.PR NewswireSightGlass Vision Announces R&D Webinar Featuring Leading Myopia ExpertsSightGlass Vision announced an upcoming R&D webinar on myopia research and treatment development, featuring leading experts Earl L. Smith III and Jay Neitz. The webinar will focus on the science of myopia, discovery of a new mechanism, and clinical trial data for the company's novel glasses aimed at slowing myopia progression in children.